Transparency Market Research

Patent Expiration to Propel the Global Biosimilar and Follow-on Biologics Market During the Forecast Period

Transparency Market Research Report Added "Biosimilar and Follow-On Biologics Market" to its database.


Albany, NY -- (SBWIRE) -- 03/24/2015 -- One of the main factors driving the global biosimilar and follow-on biologics market is patent expiration. The expansion of the follow-on biologics market can be attributed to various regulatory and commercial developments that are taking place today. The demand for cost-effective biological drugs is on the rise, which is why manufacturers these days prefer manufacturing biopharmaceuticals drugs that are generic. This enables manufacturers to ensure that these life saving drugs are priced competitively.

Follow-on biologics and biosimilars refer to the prototypes of the reference and the main biologics. These are inexpensive alternatives for biopharmaceutical drugs and are meant for chronic diseases that are affecting people all across the globe. Intellectual property rights that protect follow-on-biologics generally expire quite soon. Several blockbuster patents expired in 2014, which provided a certain competitive edge to many local pharmaceutical producers over the dominant global manufacturers. The pressing need for cost-efficient drugs coupled with rising incidence of chronic ailments are the other two prominent factors fuelling the global biosimilar and follow-on biologics market.

Early buyers will receive 10% customization on reports:

Segmentation and Scope of Application in the Global Biosimilar and Follow-On Biologics Market

The global biosimilar and follow-on biologics market is segmented on the basis of product type, technology, services, applications, and geography. The different types of products include recombinant non-glycosylated protein, recombinant glycosylated proteins, and peptides. The segment for recombinant non-glycosylated protein is further classified into human growth hormones, insulin, interferon, granulocyte colony stimulating factor, and others. The recombinant glycosylated proteins segment includes erythropoietin, monoclonal antibodies, and others. Octreotide, Desmopressin, Cyclosporine, and Calcitonin are some of the main peptides dominating the global market for biosimilar and follow-on biologics.

On the basis of technology, the global biosimilar and follow-on biologics market is segmented into bioassay, western blotting, mass spectrometry, electrophoresis, nuclear magnetic resonance technology, chromatography, recombinant DNA technology, and monoclonal antibodies technology. Clinical trials and contract research and manufacturing services are the two main segments in the global biosimilar and follow-on biologics market based on services. Based on applications, this market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others.

More than 10 Blockbuster Biosimilar Drugs to Witness Patent Expiries in Europe and the U.S.

Geographically, the global biosimilar and follow-on biologics market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). The biosimilar and follow-on biologics market in Europe is expanding due to the designing and implementation of well-disposed regulatory policies by the EMA (European Medical Association). The Asia-Pacific biosimilar and follow-on biologics market is anticipated to witness robust growth in the forthcoming years on the grounds of rising demand for biosimilars and economical medical treatment. Greater demand for cost-effective medical treatment can be attributed to rising incidence of chronic diseases in this region.

In the coming few years, more than ten blockbuster follow-on biologics with yearly sales exceeding US$60 billion will face patent expiries in the U.S. and Europe. As a result, dominant pharmaceutical manufacturers are shifting their focus from gaining approvals to launching products, with an aim towards acquiring market capitalization. A prominent market opportunity in the Asia-Pacific market for biosimilar and follow-on biologics is collaboration and business ventures with local companies. This will prove to be highly beneficial for several producers of biosimilars in the long run. Companies such as Novartis and Amgen are entering into business collaborations with Asia companies in order to acquire a foothold in the global market for biopharmaceuticals.

Prominent companies in the global biosimilar and follow-on biologics market are Genentech, Mitsubishi Tanabe Pharma Corporation, Avesta Biotherapeutics and Research (ABRPL), Avesthagen, Alexion Pharmaceuticals, Ranbaxy Laboratories, Axicorp, Astra Zeneca, Johnson & Johnson, CCL Pharmaceuticals, Sandoz, Biogen Idec, ZenotechAbraxis BioScience, Abbott, GlaxoSmithKline (GSK), CinnaGen, Cipla, 3SBio, Dr. Reddy's Laboratories, Elan Corporation, Bristol-Myers Squibb, and Amphastar Pharmaceuticals.

More Reports on Pharmaceuticals Market :

Enquiry Before Buying :

About Transparency Market Research
TMR's analysts and consultants are distinguished experts in their respective domains. The company is based on an employee-centric model and hires the best, brightest, and most passionate people in the industry. This unparalleled expertise helps TMR uncover latest market intelligence data that's distinct from the competition.

TMR is also a client-centric organization that endeavors to add value to the client's business by delivering the most insightful research. TMR understands that every client has unique product/service offerings, statement, and criteria. Customized solutions from TMR are centered on the client's problem statement. On the other hand, our syndicated research reports provide a packaged solution to keep enterprises abreast of the next major change in their industry.

Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453

Browse Market Research Blog: